Philadelphia Eye Associates

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Jul 29, 2025FDACelebrex — VYSCOXA

Nov 21, 2024FDACelebrex — CELEBREX

Apr 28, 2021FDACelebrex — CELEBREX

May 5, 2020FDACelebrex — ELYXYB

May 3, 2019FDACelebrex — CELEBREX

Jun 28, 2018FDACelebrex — CELEBREX

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

2 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Celebrex6 patentsMay 27, 2036 CelebrexSep 16, 2045

Regulatory

Regulatory Timeline

20051 event

FDAJul 29

Celebrex — CELEBREX

Application NDA020998

20062 events

FDADec 15

Celebrex — CELEBREX

Application NDA020998 (NDA)

FDADec 15

Celebrex — CELEBREX

Application NDA020998

20072 events

FDANov 2

Celebrex — CELEBREX

Application NDA020998

FDAJun 1

Celebrex — CELEBREX

Application NDA020998

20082 events

FDADec 31

Celebrex — CELEBREX

Application NDA020998

FDAJan 14

Celebrex — CELEBREX

Application NDA020998

20112 events

FDAJun 13

Avycaz — CEFTAZIDIME IN DEXTROSE CONTAINER

Application NDA050823 (NDA)

FDAFeb 4

Celebrex — CELEBREX

Application NDA020998

20121 event

FDANov 16

Celebrex — CELEBREX

Application NDA020998

20131 event

FDAJul 29

Celebrex — CELEBREX

Application NDA020998

20141 event

FDAJul 28

Celebrex — CELEBREX

Application NDA020998

20162 events

FDAMay 9

Celebrex — CELEBREX

Application NDA020998

FDAMay 9

Celebrex — CELEBREX

Application NDA020998

20181 event

FDAJun 28

Celebrex — CELEBREX

Application NDA020998

20191 event

FDAMay 3

Celebrex — CELEBREX

Application NDA020998

20201 event

FDAMay 5

Celebrex — ELYXYB

Application NDA212157 (NDA)

20211 event

FDAApr 28

Celebrex — CELEBREX

Application NDA020998

20241 event

FDANov 21

Celebrex — CELEBREX

Application NDA020998

20251 event

FDAJul 29

Celebrex — VYSCOXA

Application NDA211759 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)